Verrica Pharmaceuticals Inc. Common Stock
$4.65
$0.12 (+2.65%)
$4.57Day Range$4.79
Key Statistics
Market Cap
$79.88M
Shares Outstanding
17.2M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Jun 15, 2018
Round Lot
100
Locale
US
Trading Data
Day Open
$4.70
Day High
$4.79
Day Low
$4.57
Volume
41.3K
VWAP
$4.68
Prev Close
$4.53
Transactions
--
Acc. Volume
--
About Verrica Pharmaceuticals Inc. Common Stock
Verrica Pharmaceuticals Inc is a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers. Its commercial product and portfolio of product candidates are clinician administered therapies in areas of high unmet need. This product portfolio consists of one product with an approved indication for molluscum contagiosum, or molluscum, with the potential for several follow-on indications, as well as additional pipeline product candidates. Its commercial product, YCANTH (VP-102), for the treatment of molluscum in adult and pediatric patients two years of age and older. YCANTH (VP-102) is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin.
PHARMACEUTICAL PREPARATIONSSIC 283476 employees44 WEST GAY STREET, WEST CHESTER, PA484-453-3300IPO Jun 15, 2018US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001660334
- Composite FIGI
- BBG00L03BYB7
- Share Class FIGI
- BBG00L03BZ24
- Ticker Root
- VRCA
- SIC Code
- 2834
About Verrica Pharmaceuticals Inc. Common Stock (VRCA) Stock
Verrica Pharmaceuticals Inc. Common Stock (VRCA) closed the 2026-09-17 session at $4.65, up 2.65% versus the previous close (+0.12). The stock opened at $4.70 and traded between $4.57 and $4.79 during that session. Session trading volume was 41K shares. The volume-weighted average price (VWAP) is $4.68.
Verrica Pharmaceuticals Inc is a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers. Its commercial product and portfolio of product candidates are clinician administered therapies in areas of high unmet need. This product portfolio consists of one product with an approved indication for molluscum contagiosum, or molluscum, with the potential for several follow-on indications, as well as additional pipeline product candidates. Its commercial product, YCANTH (VP-102), for the treatment of molluscum in adult and pediatric patients two years of age and older. YCANTH (VP-102) is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin.
Verrica Pharmaceuticals Inc. Common Stock has a market capitalization of $79.9 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. VRCA is listed on the XNAS exchange. The company employs approximately 76 people. Verrica Pharmaceuticals Inc. Common Stock is headquartered in WEST CHESTER, PA. The recorded listing date is 2018-06-15.
On this page you can find market VRCA stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.